Clinical Trial Update: rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing rhTPO plus Rituximab versus low-dose Rituximab alone in immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)
• rhTPO (recombinant human thrombopoietin)

Snippet

Sponsor: Shandong University | Conditions: Purpura, Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED